Abstract:Background: Redirecting pre-existing virus-specific cytotoxic CD8+ T lymphocytes (CTLs) to tumors by simulating a viral infection of the tumor cells has great potential for cancer immunotherapy. However, this strategy is limited by lack of amenable method for viral antigen delivery into the cytosol of target tumors. Here, we addressed the limit by developing a CD8+ T cell epitope-delivering antibody, termed a TEDbody, which was engineered to deliver a viral MHC-I epitope peptide into the cytosol of target tumor cells by fusion with a tumor-specific cytosol-penetrating antibody. Methods: To direct human cytomegalovirus (CMV)-specific CTLs against tumors, we designed a series of TEDbodies carrying various CMV pp65 antigen-derived peptides. CMV-specific CTLs from blood of CMV-seropositive healthy donors were expanded for use in in vitro and in vivo experiments. Comprehensive cellular assays were performed to determine the presentation mechanism of TEDbody-mediated CMV peptide-MHC-I complex (CMV-pMHCI) on the surface of target tumor cells and the recognition and lysis by CMV-specific CTLs. In vivo CMV-pMHCI presentation and antitumor efficacy of TEDbody were evaluated in immunodeficient mice bearing human tumors. Results: TEDbody delivered the fused epitope peptides into target tumor cells to be intracellularly processed and surface displayed in the form of CMV-pMHCI, leading to disguise target tumor cells as virally infected cells for recognition and lysis by CMV-specific CTLs. When systemically injected into tumor-bearing immunodeficient mice, TEDbody efficiently marked tumor cells with CMV-pMHCI to augment the proliferation and cytotoxic property of tumor-infiltrated CMV-specific CTLs, resulting in significant inhibition of the in vivo tumor growth by redirecting adoptively transferred CMV-specific CTLs. Further, combination of TEDbody with anti-OX40 agonistic antibody substantially enhanced the in vivo antitumor activity. Conclusion: Our study offers an effective technology for MHC-I antigen cytosolic delivery. TEDbody may thus have utility as a therapeutic cancer vaccine to redirect pre-existing anti-viral CTLs arising from previously exposed viral infections to attack tumors.

Viral Specific Cytotoxic T Cells Inhibit the Growth of TfR-expressing Tumor Cells with Antibody Targeted Viral Peptide/hla-A2 Complex

Pmhc/scfv Fusion Protein Mediates Killing of Tumor Cells by Viral Specific Cytotoxic T Cells

Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1

Targeted Delivery of Interferon-Α to Hepatitis B Virus-Infected Cells Using T-cell Receptor-Like Antibodies.

Identification of α-fetoprotein-specific T cell receptors for hepatocellular carcinoma immunotherapy.

Specific Inhibition Of Tumor Growth By T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen Ny-Eso-1/Lage-1

Raising Allo-Restricted Cytotoxic T Lymphocytes by Co-Culture of Murine Splenocytes with Autologous Macrophage Bearing the Peptide/allo–major Histococompatibility Complex

Engineered Cytotoxic T Lymphocytes with AFP-specific TCR Gene for Adoptive Immunotherapy in Hepatocellular Carcinoma

Targeting activity of a TCR/IL-2 fusion protein against established tumors

Potent Killing of HBV-related Hepatocellular Carcinoma by a Chimeric Protein of Anti-Hbsag Single-Chain Antibody and Truncated Bid

Allo-Restricted Ctls Generated By Coculturing Of Pbls And Autologous Monocytes Loaded With Allogeneic Peptide/Hla/Igg1-Fc Fusion Protein

Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8+ T cells for cancer immunotherapy

Oncolytic activity of influenza A virus carrying CTLA4 antibody in hepatocellular carcinoma

Expression and in Vitro Cytotoxicity of Anti-Hepatocellular Carcinoma Single-Chain Bifunctional Antibody in Hut-78 Cell Line

Downregulation of Transferrin Receptor Surface Expression by Intracellular Antibody

Tumor Rejection Effects of Allorestricted Tumor Peptide-Specific CD4+T Cells on Human Cervical Cancer Cell Xenograft in Nude Mice

A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells